The continuous glucose monitoring (CGM) devices market is set to grow robustly regardless of the major upheaval caused by the Covid-19 pandemic. According to GlobalData’s analysis, the global CGM market was valued at $3.3bn in 2019 prior to the pandemic. GlobalData expects CGM market growth to reach mid-double digits in 2020.
The major three players in the industry, DexCom, Abbott and Medtronic, reported promising Q1 data for their CGM products. Dexcom’s revenue in Q1 grew 44% versus the same quarter of 2019 to $405.1m, while Abbott reported more than $600m for FreeStyle Libre with an increase of 62.5% versus Q1 2019. Medtronic said supplies and consumables in its Diabetes Group are in high demand, while the vast majority of Medtronic’s businesses have experienced declines.
Go deeper with GlobalData
Additionally, Dexcom’s G6 received regulatory approvals in Australia, Japan and South Korea. Abbott’s FreeStyle Libre expanded its reimbursement coverage in Japan to include people with type 2 diabetes who inject insulin multiple times daily. Therefore, the glucose monitoring market in Asia-Pacific is likely to expand exponentially in 2020.
During the Covid-19 pandemic, there has been an emphasis on the use of virtual clinics and telemedicine for diabetic management. For example, the UK’s National Health Service (NHS) updated its clinical guide to encourage remote contacts via telephone, email and video conferencing. This has resulted in an increased demand for diabetic care devices that can share data remotely.
There are significantly more data available by using CGM devices, which can help patients and healthcare providers improve glycemic control and potentially increase patient self-management. Covid-19 has opened new opportunities for the CGM systems to gain more popularity in the diabetic care market.
The surging demand for CGM is primarily driven by a growing awareness of the devices but also partly due to companies’ quick responses to the Covid-19 pandemic. Both Dexcom and Abbott have received clearance by the US Food and Drug Administration (FDA) to make their CGM systems available for use in hospital settings and other healthcare facilities. Health Canada recently announced that the Dexcom G6 CGM system has been temporarily authorised for expanded use in Canadian hospitals.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataRemote monitoring with CGM devices for patients with diabetes can help reduce exposure for healthcare providers and preserve personal protective equipment. Additionally, similar to insulin giants Novo Nordisk and Eli Lilly, CGM companies have initialised new patient assistance programmes to support current CGM customers who have lost insurance due to the Covid-19 pandemic in the US. Dexcom reduced its CGM cost to $45 per 90-day supply for its existing, qualified patients.
However, the CGM startup company Senseonics has been severely hit by Covid-19. Unlike other CGM devices, the sensors used in its Eversense CGMs require in-clinic procedures that have decreased greatly due to the outbreak. The company suspended its sales and marketing efforts to acquire new users of CGM to reduce commercial costs. As a result, the current top players in the CGM market are expected to strengthen their leadership in 2020.
Related Company Profiles
Novo Nordisk AS
Senseonics Inc
DexCom Inc
Medtronic Plc
CGM SpA